Immunohistochemical analysis of medullary breast carcinoma autoantigens in different histological types of breast carcinomas
1 Department of Cell Signaling, Institute of Molecular Biology and Genetics, NAS of Ukraine, 150, Zabolotnogo str., Kyiv, Ukraine
2 Educational and Scientific Centre “Institute of Biology”, Taras Shevchenko National University of Kyiv, 64, Volodymyrs’ka Str., Kyiv, Ukraine
3 Dnipropetrovsk Clinical Oncological Center, Dnipropetrovsk, Ukraine
Citation and License
Diagnostic Pathology 2012, 7:161 doi:10.1186/1746-1596-7-161Published: 26 November 2012
On the past decade a plethora of investigations were directed on identification of molecules involved in breast tumorogenesis, which could represent a powerful tool for monitoring, diagnostics and treatment of this disease. In current study we analyzed six previously identified medullary breast carcinoma autoantigens including LGALS3BP, RAD50, FAM50A, RBPJ, PABPC4, LRRFIP1 with cancer restricted serological profile in different histological types of breast cancer.
Semi-quantitative immunohistochemical analysis of 20 tissue samples including medullary breast carcinoma, invasive ductal carcinoma, invasive lobular carcinoma and non-cancerous tissues obtained from patients with fibrocystic disease (each of five) was performed using specifically generated polyclonal antibodies. Differences in expression patterns were evaluated considering percent of positively stained cells, insensitivity of staining and subcellular localization in cells of all tissue samples.
All 6 antigens predominantly expressed in the most cells of all histological types of breast tumors and non-cancerous tissues with slight differences in intensity of staining and subcellular localization. The most significant differences in expression pattern were revealed for RAD50 and LGALS3BP in different histological types of breast cancer and for PABPC4 and FAM50A antigens in immune cells infiltrating breast tumors.
This pilot study made possible to select 4 antigens LGALS3BP, RAD50, PABPC4, and FAM50A as promising candidates for more comprehensive research as potential molecular markers for breast cancer diagnostics and therapy.
The virtual slides’ for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/1860649350796892 webcite